Cerulean crash­es af­ter lead nano drug flubs its sec­ond PhII can­cer study

Cerulean Phar­ma’s lead nan­otech can­cer drug has run in­to an­oth­er stone wall in the clin­ic. The Waltham, MA-based biotech $CERU says that CR­LX101 com­bined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.